Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare.
$13.57+2.73%
报价 2026-11-06
市值
$3.71B
EV
–
PE (TTM)
23.9x
预期 PE (FY2026)
–
52 周区间距高点 -44.0%
$13.21$24.25
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Medical - Instruments & Supplies| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| STVNStevanato Group S.p.A. | $3.71B | +2.7% | +8.3% | 29.1% | 23.9x | 12.0x | – | |
| BLCOBausch + Lomb Corporation | $7.15B | +0.4% | +8.2% | 60.5% | – | 17.1x | 28.2x | |
| TFXTeleflex Incorporated | $6.39B | -0.8% | -30.7% | 53.3% | – | 63.6x | 26.1x | |
| HAEHaemonetics Corporation | $5.46B | -3.4% | +7.0% | 59.8% | 58.9x | 24.8x | 18.9x | |
| MMSIMerit Medical Systems, Inc. | $5.23B | -2.7% | +7.1% | 48.7% | 31.5x | 13.5x | 20.7x | |
| ICUIICU Medical, Inc. | $4.3B | +2.7% | -0.8% | 36.4% | 90.1x | 20.0x | 52.4x | |
| PLSEPulse Biosciences, Inc. | $3.87B | +0.4% | +1900.0% | 51.6% | – | – | – | 高增长 |
| ATRCAtriCure, Inc. | $2.98B | -4.5% | +13.7% | 77.3% | 194.5x | 73.5x | 51.4x | GARP |
| WRBYWarby Parker Inc. | $2.77B | -2.3% | +10.8% | 54.4% | 424.7x | 41.6x | 129.6x | GARP |
| 同行中位数 | – | – | +7.7% | 53.9% | 90.1x | 24.8x | 28.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 EUR（非美元）| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | €324.2M | €302M | €273.6M | €343.3M | €303.2M | €280M | €256.6M | €330.6M |
| Gross Margin | 29.1% | 28.7% | 27.5% | 30.9% | 29.2% | 28.1% | 27.2% | 29.7% |
| Operating Margin | 17.6% | 12.9% | 14.2% | 19.2% | 17.4% | 14.8% | 13.5% | 20.2% |
| Net Income | €41.6M | €23M | €28M | €47.2M | €36.1M | €29.7M | €26.5M | €48.3M |
| Diluted EPS | 0.16 | 0.08 | 0.1 | 0.17 | 0.13 | 0.11 | 0.1 | 0.18 |
| Operating Cash Flow | €56.2M | €31.9M | €75.5M | €92.5M | €47.2M | €44.9M | €99.8M | €43.6M |
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。